SWOG Cancer Research Network
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956. Member NCTN & NCORP. Online at swog.org. @SupportingSWOG.bsky.social partner.
- Reposted by SWOG Cancer Research NetworkThe latest @swog.org Front Line: A Cancer Research Agenda for the Nation, and for SWOG #SWOGonc www.swog.org/news-events/...
- "Cancer statistics, 2026: Charting a course for a national cancer research agenda," commentary by Dr. Primo Lara, Jr, & @drdawnhershman.bsky.social publ w the annual portrait of U.S. #cancer stats in CA: A Cancer Journal for Clinicians, just out! #NCTN #NCORP @eaonc.bsky.social @nrgonc.bsky.social
- S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis. BMT-CTN Champion: Anita D'Souza, MD SWOG.org/clinical-trials/S2213
- Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT). SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
- Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC
- S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
- Reposted by SWOG Cancer Research NetworkFor all #SWOGonc early career GU researchers: The Nicholas Vogelzang GU Scholars Program Includes mentorship and travel support - apply by January 15 w/ @swog.org thehopefoundation.org/vogelzang-gu...
- #ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.
- Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next? If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT). Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
- Reposted by SWOG Cancer Research NetworkIn a multi-trial analysis led by Fred Hutch's Dr. Joe Unger, patients reporting fatigue prior to systemic cancer treatment faced 2x the risk for severe toxic effects and nearly 5x the risk for fatal complications compared with those with minimal to no fatigue. @swog.org wb.md/3LozLE8
- Just activated! #NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm PI: Rachael A. Safyan, MD @fredhutch.org swog.org/clinical-tri...
- In @jamaoncology.com: higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org
- Among over 7000 patients with #cancer, higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. ja.ma/4qmZtrt
- S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis. ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD SWOG.org/clinical-trials/S2213
- Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC
- Reposted by SWOG Cancer Research NetworkOur program offerings kick off right away in 2026. #SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting! thehopefoundation.org/funding-oppo...
- If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
- Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial
- Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials doi.org/10.1158/1078...
- #ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype. Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center swog.org/clinical-trials/S2409
- S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT. PROs track QoL and treatment-related symptomatic toxicities. Systematic biopsies needed at post-NAT TURBT. Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center swog.org/clinical-trials/S2427
- If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
- Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC
- What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates. TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine SWOG.org/clinical-trials/S2213
- Reposted by SWOG Cancer Research NetworkAwesome 👏🏾 Barbara 👏🏾 Honored to be included in Barbara Segarra’s plenary session @sabcs.bsky.social and proud to work alongside you! @swog.org @oncoalert.bsky.social @oncodaily.bsky.social #bcsm #breastcancer #advocates #oncoalert #clinicaltrials #research #SABCS25
- Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease
- The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM Co-PI: So Yeon Kim, MD Yale Cancer Center swog.org/clinical-trials/S2409
- S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT. Focal, non-diffuse carcinoma in situ (CIS) is allowed. Systematic biopsies needed at post-NAT TURBT. Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine swog.org/clinical-trials/S2427
- Reposted by SWOG Cancer Research NetworkOne great thing our donors do? Help send @swog.org patient advocates to key scientific meetings like #SABCS25 Cheers to @barbarasegarra.bsky.social and Cheryl Jernigan who will be featured/contributing this week! #SWOGonc www.swog.org/news-events/...
- AL #amyloidosis trial S2213 compares autologous transplant to Dara-VCD consolidation. Also compares post-consolidation #PatientReportedOutcomes for physical function and other #HRQoL measures. QoL/PRO Co-PI: Terri Parker, MD Yale Cancer Center SWOG.org/clinical-trials/S2213
- S2427 (BRIGHT) is a study for people who were treated for muscle invasive #BladderCancer — and the cancer shrunk or can’t be found after treatment. The study asks if a drug plus radiation can help prevent bladder removal. Visit SWOG.org/S2427. Or call 1-800-4-CANCER.
- S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit SWOG.org/S2409. Or call 1-800-4-CANCER. #LCSM
- Our @swog.org group chair's Front Line blog: SWOG at SABCS: A Record of Success The San Antonio Breast Cancer Symposium has been a prime venue for publishing important SWOG research results in breast cancer treatment, symptom management, and prevention. #SABCS25 www.swog.org/news-events/...
- Reposted by SWOG Cancer Research NetworkFred Hutch's Min Fang presenting work at #ASH25 showing chromosome genomic array testing (CGAT) improves diagnostic yield in patients with #AML and #MDS and has the potential for better risk stratification - an NCI myeloMATCH and @swog.org report. ashpublications.org/blood/articl...
- Enrolling: SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance. Co-PI: @surbhisidanamd.bsky.social Stanford Medicine SWOG.org/clinical-trials/S2213
- #Clinicaltrial S2213 asks if a drug combination (called Dara-VCD) or stem cell transplant is better for people with AL #amyloidosis. The trial is for people who haven’t started treatment yet. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER.
- Thank you to donors and to @supportingswog.bsky.social for ALL you make possible!
- *Thank you* - today and every day - to the donors who make our work possible. Learn about some of what's happening in 2026, including early deadlines for research and travel support opportunities. Together, we're moving cancer research forward #SWOGonc @swog.org conta.cc/4pJyxC3
- S2409 PRISM is testing whether it’s feasible to identify each patient’s small cell #LungCancer subtype and use that information to select the best therapy for that patient. #SCLC Co-PI: Alberto Chiappori, MD Moffitt Cancer Center swog.org/clinical-trials/S2409
- If patients w #MIBC have a clinically sig response to NAT, is cystectomy needed? S2427 BRIGHT trial tests whether pembro + RT can let patients keep their bladder. Systematic biopsies needed at post-NAT TURBT. Co-PI: Abhishek Tripathi, MD City of Hope swog.org/clinical-trials/S2427
- The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more: dctd.cancer.gov/about/news-e... @swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP
- Our @swog.org group chair's Front Line blog: Thank You Through a year that’s had more than its share of uncertainties, I’m thankful for you, SWOG’s members and supporters, for all you do to care for our patients and advance our research. www.swog.org/news-events/...
- Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: CAR-T Cells in Solid Tumors: Challenges and Breakthroughs doi.org/10.1016/j.xc...
- Study S2213 is for people with newly diagnosed #ALAmyloidosis. It compares a combination of immunotherapy and chemo drugs (called Dara-VCD) to stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. Ask about S2213. #raredisease #mmsm
- S2427 BRIGHT trial: In patients with #MIBC, can immunoradiotherapy after response to neoadj therapy (cT0/cT1) allow for bladder preservation? Systematic biopsies needed at post-NAT TURBT pre-registration. Co-PI: S. Daneshmand, MD USC Norris Comprehensive Cancer Center swog.org/clinical-trials/S2427
- The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM PI: Anne Chiang, MD, PhD - Yale Cancer Center swog.org/clinical-trials/S2409
- Our @swog.org group chair's Front Line blog: SWOG Is All Over ASH 2025 #ASH25 will feature a sizeable group of posters and presentations reporting on (or responding to) SWOG research. Here are some highlights. www.swog.org/news-events/...
- Consider S2427 BRIGHT for your pts with #MIBC getting neoadj therapy. If systematic biopsies at post-NAT TURBT show cT0 or cT1, pt may be eligible for S2427. Can IO + RT be bladder-preserving? #BladderCancer PI: Leslie Ballas, MD Cedars-Sinai Cancer swog.org/clinical-trials/S2427
- Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: Bispecific Antibodies and Nanotechnology: A Strategic Alliance in Cancer Immunotherapy doi.org/10.1186/s129...
- Reposted by SWOG Cancer Research NetworkYou have a great research idea? A critical need to address? Let's tackle it together. We agree: "...while Hope is often referred to as SWOG’s public charity, it has become so, so much more." We're honored to help advance #SWOGonc research & grateful to all who make it possible. Thank you!
- Our @swog.org group chair's Front Line blog: **This Thanksgiving, It's All About Hope** Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social. www.swog.org/news-events/...
- Our @swog.org group chair's Front Line blog: **This Thanksgiving, It's All About Hope** Thanksgiving is still a couple of weeks out, but high on my list of what I’m thankful for is having the strong support of @supportingswog.bsky.social. www.swog.org/news-events/...
- Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Targeting DNA Repair Mechanisms in Cancer Therapy: The Role of Small Molecule DNA Repair Inhibitors academic.oup.com/narcancer/ar...
- Reposted by SWOG Cancer Research NetworkSupporting Veterans with Access to Better Care 10 years of our @swog.org VA Integration and Storefront grant programs #SWOGonc conta.cc/43SSei3
- From our @swog.org group chair's Front Line blog: Stories of SWOG Accrual Stars We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials. www.swog.org/news-events/...
- Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: WNT Signaling in Cancer: Molecular Mechanisms and Potential Therapies doi.org/10.1186/s435...
- Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S. lung-map.org @focr.bsky.social @swog.org
- Our @swog.org group chair's Front Line blog: Group Meeting Surveys: You "Talk," We Listen SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say? www.swog.org/news-events/...
- Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights doi.org/10.1177/1179...
- Our @swog.org group chair's Front Line blog: SWOG Research Demonstrates the Special Role of Federal Sponsorship Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research. www.swog.org/news-events/...
- Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD: Overcoming Resistance to Anti-PD-L1 Immunotherapy: Mechanisms, Combination Strategies, and Future Directions doi.org/10.1186/s129...
- Latest results from @swog.org DART rare cancers trial, out in J for ImmunoTherapy of Cancer: Multicenter phase II trial of ipilimumab & nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of DART SWOG S1609 (Cohort 38) jitc.bmj.com/content/13/1...
